Johnson & Johnson PE Ratio 2010-2024 | JNJ
Current and historical p/e ratio for Johnson & Johnson (JNJ) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Johnson & Johnson PE ratio as of December 20, 2024 is 14.02.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Johnson & Johnson PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-12-20 |
144.47 |
|
20.91 |
| 2024-09-30 |
160.77 |
$6.91 |
23.27 |
| 2024-06-30 |
143.90 |
$16.01 |
8.99 |
| 2024-03-31 |
154.48 |
$16.04 |
9.63 |
| 2023-12-31 |
151.91 |
$13.81 |
11.00 |
| 2023-09-30 |
149.76 |
$13.47 |
11.12 |
| 2023-06-30 |
158.02 |
$4.94 |
31.99 |
| 2023-03-31 |
146.87 |
$4.78 |
30.73 |
| 2022-12-31 |
166.21 |
$6.74 |
24.66 |
| 2022-09-30 |
152.72 |
$7.18 |
21.27 |
| 2022-06-30 |
164.84 |
$6.87 |
23.99 |
| 2022-03-31 |
163.55 |
$7.42 |
22.04 |
| 2021-12-31 |
156.85 |
$6.14 |
25.55 |
| 2021-09-30 |
147.10 |
$5.70 |
25.81 |
| 2021-06-30 |
149.16 |
$5.69 |
26.21 |
| 2020-12-31 |
140.74 |
$5.51 |
25.54 |
| 2020-09-30 |
132.21 |
$6.36 |
20.79 |
| 2020-06-30 |
124.06 |
$6.84 |
18.14 |
| 2020-03-31 |
114.87 |
$7.56 |
15.19 |
| 2019-12-31 |
126.96 |
$6.78 |
18.73 |
| 2019-09-30 |
111.83 |
$6.40 |
17.47 |
| 2019-06-30 |
120.39 |
$6.03 |
19.97 |
| 2019-03-31 |
120.01 |
$5.40 |
22.22 |
| 2018-12-31 |
110.06 |
$5.61 |
19.62 |
| 2018-09-30 |
117.09 |
$0.50 |
234.19 |
| 2018-06-30 |
102.15 |
$0.43 |
237.56 |
| 2018-03-31 |
107.09 |
$0.38 |
281.82 |
| 2017-12-31 |
116.02 |
$0.39 |
297.49 |
| 2017-09-30 |
107.31 |
$5.76 |
18.63 |
| 2017-06-30 |
108.49 |
$5.92 |
18.33 |
| 2017-03-31 |
101.48 |
$5.95 |
17.06 |
| 2016-12-31 |
93.26 |
$5.88 |
15.86 |
| 2016-09-30 |
94.97 |
$5.65 |
16.81 |
| 2016-06-30 |
96.87 |
$6.44 |
15.04 |
| 2016-03-31 |
85.80 |
$6.21 |
13.82 |
| 2015-12-31 |
80.87 |
$6.28 |
12.88 |
| 2021-03-31 |
147.89 |
$6.66 |
22.21 |
| 2015-09-30 |
72.96 |
$5.23 |
13.95 |
| 2015-06-30 |
75.58 |
$5.69 |
13.28 |
| 2015-03-31 |
77.45 |
$5.59 |
13.85 |
| 2014-12-31 |
79.94 |
$5.70 |
14.03 |
| 2014-09-30 |
80.96 |
$6.04 |
13.40 |
| 2014-06-30 |
78.93 |
$5.42 |
14.56 |
| 2014-03-31 |
73.60 |
$5.24 |
14.05 |
| 2013-12-31 |
68.13 |
$4.82 |
14.14 |
| 2013-09-30 |
64.04 |
$4.50 |
14.23 |
| 2013-06-30 |
62.96 |
$4.51 |
13.96 |
| 2013-03-31 |
59.34 |
$3.68 |
16.12 |
| 2012-12-31 |
50.61 |
$3.87 |
13.08 |
| 2012-09-30 |
49.32 |
$3.04 |
16.22 |
| 2012-06-30 |
47.92 |
$3.14 |
15.26 |
| 2012-03-31 |
46.34 |
$3.64 |
12.73 |
| 2011-12-31 |
45.67 |
$3.48 |
13.12 |
| 2011-09-30 |
43.94 |
$4.10 |
10.72 |
| 2011-06-30 |
45.49 |
$4.18 |
10.88 |
| 2011-03-31 |
40.17 |
$4.41 |
9.11 |
| 2010-12-31 |
41.56 |
$4.78 |
8.69 |
| 2010-09-30 |
41.27 |
$4.87 |
8.48 |
| 2010-06-30 |
38.98 |
$4.84 |
8.05 |
| 2010-03-31 |
42.64 |
$4.76 |
8.96 |
| 2009-12-31 |
41.80 |
$4.40 |
9.50 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$345.687B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
